Human coronary arteriolar dilation to adrenomedullin: role of nitric oxide and K(+) channels.

Adrenomedullin (ADM) is a vasodilator produced by vascular endothelium and smooth muscle cells. Although plasma ADM levels are increased in patients with hypertension, heart failure, and myocardial infarction, little information exists regarding the microvascular response to ADM in the human heart. In the present study we tested the hypothesis that ADM produces coronary arteriolar dilation in humans and examined the mechanism of this dilation. Human coronary arterioles were dissected and cannulated with micropipettes. Internal diameter was measured by video microscopy. In vessels constricted with ACh, the diameter response to cumulative doses of ADM (10(-12)-10(-7) M) was measured in the presence and absence of human ADM-(22-52), calcitonin gene-related peptide-(8-37), N(omega)-nitro-L-arginine methyl ester (L-NAME), indomethacin (Indo), (1)H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one, SQ-22536, or KCl (60 mM). ADM dilated human coronary arterioles through specific ADM receptors (maximum dilation = 69 +/- 11%). L-NAME or N-monomethyl-L-arginine attenuated dilation to ADM (for L-NAME, maximum dilation = 66 +/- 7 vs. 41 +/- 13%, P < 0.05). Thus the mechanism of ADM-induced dilation involves generation of nitric oxide. However, neither (1)H-[1,2,4]oxadiazolo-[4, 3-a]quinoxalin-1-one, SQ-22536, nor Indo alone altered dilation to ADM. High concentrations of KCl blocked dilation to ADM. The magnitude of ADM dilation was reduced in subjects with hypertension. We propose that, in human coronary arterioles, ADM elicits vasodilation in part through production of nitric oxide and in part through activation of K(+) channels, with little contribution from adenylyl cyclase. The former dilator mechanism is independent of the more traditional pathway involving activation of soluble guanylate cyclase.

[1]  H. Miura,et al.  Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels. , 1999, Circulation.

[2]  H. Nishimatsu,et al.  Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat. , 1999, Hypertension.

[3]  H. Ozaki,et al.  Effects of adrenomedullin and calcitonin gene‐related peptide on contractions of the rat aorta and porcine coronary artery , 1998, British journal of pharmacology.

[4]  K. Kangawa,et al.  Plasma levels of adrenomedullin in patients with acute myocardial infarction. , 1998, Clinical science.

[5]  J. Cockcroft,et al.  Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels. , 2003, British journal of clinical pharmacology.

[6]  K. Kangawa,et al.  Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. , 1997, Hypertension.

[7]  H. Hidaka,et al.  Effects of adrenomedullin on rat cerebral arterioles. , 1997, European journal of pharmacology.

[8]  K. Kangawa,et al.  Production of adrenomedullin in human vascular endothelial cells. , 1997, Life sciences.

[9]  N. Arakawa,et al.  Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. , 1997, Circulation.

[10]  H. Lippton,et al.  Adrenomedullin mediates coronary vasodilation through adenosine receptors and KATP channels. , 1997, The Journal of surgical research.

[11]  Y. Nishimura,et al.  RELAXANT EFFECTS OF VASODILATOR PEPTIDES ON ISOLATED BASILAR ARTERIES FROM STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS , 1997, Clinical and experimental pharmacology & physiology.

[12]  D. Heistad,et al.  Mechanisms of adrenomedullin-induced dilatation of cerebral arterioles. , 1997, Stroke.

[13]  R. Rodeheffer,et al.  Cardiac secretion of adrenomedullin in human heart failure. , 1996, The Journal of clinical investigation.

[14]  A. Kaye,et al.  Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. , 1996, The American journal of physiology.

[15]  Y. Koiwaya,et al.  Increased plasma adrenomedullin in acute myocardial infarction. , 1996, American heart journal.

[16]  J. Yoshikawa,et al.  Plasma adrenomedullin concentrations in essential hypertension. , 1996, Hypertension.

[17]  J. Burnett,et al.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.

[18]  T. Horio,et al.  Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. , 1995, Hypertension.

[19]  K. Kangawa,et al.  Receptors for adrenomedullin in human vascular endothelial cells. , 1995, European journal of pharmacology.

[20]  Y. Kambayashi,et al.  Adrenomedullin Stimulates Two Signal Transduction Pathways, cAMP Accumulation and Ca2+ Mobilization, in Bovine Aortic Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[21]  S. Gardiner,et al.  Regional haemodynamic effects of human and rat adrenomedullin in conscious rats , 1995, British journal of pharmacology.

[22]  B. Nossaman,et al.  Comparative effects of adrenomedullin, an adrenomedullin analog, and CGRP in the pulmonary vascular bed of the cat and rat. , 1994, Life sciences.

[23]  R. Raffa,et al.  Alpha2-adrenoceptors vs. imidazoline receptors: implications for α2-mediated analgesia and other non-cardiovascular therapeutic uses , 1995 .

[24]  T. Cocks,et al.  Pharmacological reactivity of human epicardial coronary arteries: characterization of relaxation responses to endothelium‐derived relaxing factor , 1994, British journal of pharmacology.

[25]  Y. Hirata,et al.  Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells. , 1994, Endocrinology.

[26]  T. Ishimitsu,et al.  Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. , 1994, The Journal of clinical investigation.

[27]  N. Minamino,et al.  Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. , 1994, Biochemical and biophysical research communications.

[28]  K. Miyamoto,et al.  Endothelial cells actively synthesize and secrete adrenomedullin. , 1994, Biochemical and biophysical research communications.

[29]  N. Minamino,et al.  Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. , 1994, Biochemical and biophysical research communications.

[30]  K. Kangawa,et al.  Immunoreactive adrenomedullin in human plasma , 1994, FEBS letters.

[31]  F. Marumo,et al.  Specific receptors for adrenomedullin in cultured rat vascular smooth muscle cells , 1994, FEBS letters.

[32]  A. Kaye,et al.  L-NAME modulates responses to adrenomedullin in the hindquarters vascular bed of the rat. , 1994, Life sciences.

[33]  K. Kangawa,et al.  Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. , 1993, Biochemical and biophysical research communications.

[34]  K. Kangawa,et al.  Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. , 1993, European journal of pharmacology.

[35]  K. Kangawa,et al.  Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.

[36]  M. Marcus,et al.  Microvascular distribution of coronary vascular resistance in beating left ventricle. , 1986, The American journal of physiology.